LX2006 Gene Therapy Shows Early Signals of Cardiac Benefit in Friedreich Ataxia Cardiomyopathy
Key Points Friedreich ataxia (FA) is a rare, progressive, autosomal recessive disorder caused by mutations in the frataxin (FXN) gene, leading to mitochondrial dysfunction... Read more.
Next-generation Cardiac Myosin Inhibitor- BHB/HRS-1893- Promising in Reducing LVOT Gradient in Obstructive HCM: Phase 2 Results
Key Points Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by dynamic left ventricular outflow tract (LVOT) obstruction, leading to symptoms of dyspnea,... Read more.
Anti-fibrotic Therapy After TAVI Improved Myocardial Fibrosis Regression and Quality of Life: Reduce-MFA Trial
Key Points Myocardial fibrosis is a key driver of adverse cardiac remodeling and heart failure progression in patients with severe aortic stenosis (AS), and its... Read more.
NPR1 Agonist XXB750 Fails to Improve Cardiac Biomarkers and Increases Heart Failure Events in Phase 2 Trial
Key Points In an Investigative Horizons session at the American College of Cardiology 2026 Scientific Sessions, Dr. Scott Solomon from Mass General Brigham Boston,... Read more.
Indigenous “Food is Medicine” Program Reduced Hospitalizations in Heart Failure Patients in MUTTON-HF Trial
Key Points Nutrition insecurity is a major driver of cardiovascular health disparities in Indigenous communities, particularly among patients with heart failure... Read more.
Mobile App–Based Sodium Reduction Strategy Did Not Improve SBP in LowSalt4Life 2 Trial
Key Points: Excess dietary sodium intake remains a major contributor to hypertension and cardiovascular disease, with most Americans consuming well above recommended... Read more.
POLY-HF: Polypill for HFrEF Shows Promise in Reducing Medication Burden Among Underserved Patients
Key Points: Patients with heart failure with reduced ejection fraction (HFrEF) often face a high daily pill burden, contributing to poor adherence to guideline-directed... Read more.
ABLATION Trial – Biatrial Ablation During Mitral Valve Surgery Better than LA Ablation Alone
Key Points: Persistent atrial fibrillation (AF) is common among patients with rheumatic mitral valve disease undergoing surgery, but the optimal surgical ablation... Read more.
OPTIMA-AF Trial – One-month Dual Therapy After PCI Non-inferior to 12 Months, With Lower Bleeding in AF Patients
Key Points: • In patients with atrial fibrillation (AF) undergoing PCI, prolonged dual antithrombotic therapy increases bleeding risk. • OPTIMA-AF tested whether... Read more.
DARE-AF Trial: Dapagliflozin Did Not Reduce AF Burden After Catheter Ablation
Key Points: SGLT2 inhibitors have shown potential antiarrhythmic benefits in cardiometabolic disease, but their role in low-risk AF patients is unknown. DARE-AF... Read more.